Dicerna Pharmaceuticals

$26.98
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$1.33 (-4.70%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell DRNA and other stocks, options, and ETFs commission-free!

About DRNA

Dicerna Pharmaceuticals, Inc. Common Stock, also called Dicerna Pharmaceuticals, is a biopharmaceutical company, which engages in the discovery and development of treatments for rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson and John J. Rossi in 2007 and is headquartered in Watertown, MA. The listed name for DRNA is Dicerna Pharmaceuticals, Inc. Common Stock.

CEO
Douglas M. Fambrough, III, PhD
Employees
187
Headquarters
Lexington, Massachusetts
Founded
2007
Market Cap
2.04B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
811.62K
High Today
$28.25
Low Today
$25.56
Open Price
$27.72
Volume
1.73M
52 Week High
$29.45
52 Week Low
$11.75

DRNA News

BenzingaFeb 25

Recap: Dicerna Pharmaceuticals Q4 Earnings

Shares of Dicerna Pharmaceuticals (NASDAQ:DRNA) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share

DRNA Earnings

-$0.58
-$0.20
$0.17
$0.55
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
-$0.03 per share
Actual
-$0.49 per share
Replay Earnings Call

You May Also Like

GYLD
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure